Corpus cavernosum smooth muscle relaxation and hence penile erection are regulated in part by increases in smooth muscle synthesis of the second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). The object of this study was to determine 30-month follow-up results in motivated patients desiring noninvasive medical therapy using sildenafil citrate (Viagra) in combination with intraurethral prostaglandin E 1 (PGE 1 ) (Medicated Urethral System for Erection [MUSE]). Twenty-eight patients (mean AE s.d. age, 59 AE 7.3 y; 17 who had undergone radical prostatectomy and 11 who had a diagnosis of organic erectile dysfunction) were included in this study. Detailed history taking and physical examinations were performed and vascular risk factors noted. In these patients, treatment with either 100 mg of sildenafil citrate and=or 1000 m mg of MUSE had failed. None of these patients desired intracavernosal injection. Duplex Doppler ultrasonography after redosing was carried out on all patients. Dynamic infusion corpus cavernosography=cavernosometry was obtained in 17 of 28 patients, and combination therapy was initiated using 100 mg of sildenafil citrate orally 60 min before intercourse and 500 m mg of MUSE intraurethrally immediately before intercourse. Independently, either 100 mg of sildenafil citrate or 1000 m mg of MUSE was not efficacious in inducing an erection sufficient for vaginal penetration in any of the 28 patients. After initiating a combination therapy, at 30 months, all 28 patients were reporting erections sufficient for vaginal penetration, with 3.6 intercourse episodes per month. None of the patients crossed over to intracavernosal therapy or penile prosthesis. During therapy, eight of 28 patients reduced the dose of sildenafil citrate to 50 mg. Combination therapy with MUSE and sildenafil may be more efficacious in the salvage of patients who desire noninvasive therapy but in whom single-treatment modalities fail. Although both cAMP-and cGMP-mediated vasodilation can lead to penile erection, combining therapies that incorporate both pathways may succeed when single therapies fail.
Introduction
The advent of oral sildenafil citrate (Viagra) has heralded a new wave of enthusiasm by patients seeking noninvasive treatment for male erectile dysfunction. Unfortunately, the efficacy and outcomes determined in the general urology practice may not compare to the clinical trials conducted both with healthy volunteers and subsequently with patients with minimal and moderate erectile dysfunction. 1 -5 A recent report from a general urology practice notes some of these discrepancies. 6 Further, differences in objective assessment of tumescence and frequency of penetration, as assessed by the International Index of Erectile Function (IIEF), have been highlighted in two recent cohorts: patients with spinal cord injury 3, 4 and diabetic patients. 5 In the spinal cord injury group, although a significant improvement was documented in sexual satisfaction, there was no significant difference in penile rigidity between the placebo-and sildenafil-treated patients as documented by the IIEF. 3, 4 In the diabetic cohort, there was a significant difference in both parameters (tumescence and penetration); however, a large number of patients were not successful in intercourse attempts. 4 Likewise, the initial success of the Medical Urethral System for Erection (MUSE) (intraurethral prostaglandin E 1 [PGE 1 ]) 7, 8 has been difficult to duplicate in the office setting. 9 -11 It is also important to note the different mechanisms by which sildenafil and PGE 1 relax the corpus cavernosum trabecular smooth muscle, albeit by different pathways, and hence facilitate erection. 1 Corpus cavernosum smooth muscle relaxation and hence penile erection are regulated in part by increases in smooth muscle synthesis of the second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). 1 There are indirect-and direct-acting smooth muscle-relaxing agents. Phosphodiesterase (PDE) inhibitors such as sildenafil act indirectly and require sexual stimulation and endogenous nitric oxide production for efficacy, activating the cGMP pathway. In contrast, agents such as PGE 1 act directly on the trabecular smooth muscle, binding to specific EP receptors and increasing cAMP synthesis. 1, 9 As such, the direct-acting agents do not require sexual stimulation for efficacy.
In this report, we examine the effectiveness of MUSE-sildenafil combination therapy in 28 motivated patients in whom each individual therapy had failed but who did not wish to have more invasive therapies such as intracavernosal injection.
Methods
Twenty-eight patients (17 who had undergone radical prostatectomy and 11 who had a diagnosis of organic erectile dysfunction) with a mean AE s.d. age of 59 y (range, 51 -66 y) who did not desire intracavernosal therapy were included in this study. A detailed history taking and physical examination were performed and vascular risk factors noted ( Table 1 ). Fifteen of 17 prostatectomy patients had undergone bilateral nerve-sparing radical retropublic prostatectomies (RRPs), whereas the remaining two prostatectomy patients had undergone unilateral nerve-sparing procedures. The RRPs had been performed less than 5 months previously in all patients at the time of initiation of therapy. Patients were instructed to self-titrate themselves to a dose of either 100 mg of sildenafil citrate and=or 1000 mg of MUSE intraurethrally before consideration of combination therapy. Duplex Doppler ultrasonography with redosing was performed in all of the patients before combination therapy. In all of the radical prostatectomy patients, dynamic infusion corpus cavernosometry=cavernosography was performed after redosing. 10 None of these patients desired intracavernosal injection, and combination therapy was initiated using 100 mg of sildenafil citrate orally 60 min before intercourse and 500 mg of MUSE intraurethrally immediately before intercourse.
Results
Vascular risk factors have been associated with and can be predictive of erectile dysfunction. 1 Of the radical prostatectomy patients in our study, all had only one vascular risk factor. None of these patients were obese (body mass index [BMI] > 30), had sleep apnea, or reported smoking. Four reported hypertension, with one using diet to control the condition. Three reported type 2 diabetes mellitus. With the organic erectile dysfunction patients, none of the patients were obese or reported sleep apnea. Of the seven that reported hypertension, two also complained of diabetes. Aside from those two Five patients had a smoking history of 10 pack-years but stopped more than 15 y ago. c Two patients had hypertension and diabetes. d Currently, n ¼ 2; 0.5 packs per day for the last 20 y; six of nine patients stopped smoking more than 12 y ago.
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A Nehra et al patients, all had one vascular risk factor. Blood work revealed that all hormonal values in both sets of patients were within normal limits. On examination with duplex Doppler ultrasonography following intracavernous injection of PGE 1 (10 mg) for diagnosis, of the 11 patients with potential organic erectile dysfunction, three had defined veno-occlusive dysfunction and two had cavernosal artery insufficiency, all despite redosing. All of the RRP patients had normal cavernosal inflows as assessed by duplex Doppler ultrasonography. The RRP patients were further subjected to dynamic infusion corpus cavernosometry= cavernosography. All 17 patients were diagnosed as having veno-occlusive dysfunction with diffuse leakage present at crural (2 þ ), dorsal (2 þ ), cavernosal (1 þ ), and spongiosal (1 þ ) sites.
This entire cohort of patients was typified by a high degree of motivation to treat their erectile dysfunction and substantial anxiety regarding intracavernous injection therapy or surgery and the ability to regain sexual function. In all patients, 100 mg of sildenafil citrate or 1000 mg of MUSE independently, although inducing some penile tumescence, was not efficacious in facilitating an erection sufficient for vaginal penetration. This corroborates the poor response of radical prostatectomy patients treated with sildenafil recently reported, 6 but disagrees with the success other clinicians have found with bilateral nerve-sparing radical prostatectomy patients who are undergoing sildenafil therapy. 12 Further, these observations are consistent with the mixed responses noted with patients using MUSE. 11, 13, 14 After the first regimen of treatment failed, these highly anxious, self-motivated patients began combination therapy. Initial dosing was performed in the office setting to closely monitor any adverse effects. No positional hypotension, priapism, or other cardiovascular episodes were noted in any of the 28 patients. Further, there was no evidence of abnormal electrocardiogram results, angina, or peripheral vascular complications. Combination therapy, including a lower dose of MUSE (500 mg) and 100 mg of sildenafil citrate, was most effective in inducing an erection sufficient for vaginal penetration. At 30 months, all patients are reporting reproducible results and continue to use the combination therapy, with 3.6 intercourse episodes per month. None have crossed over to intracavernosal therapy or penile prosthesis. During therapy, eight of the 28 patients had reduced their dose of sildenafil citrate to 50 mg. The General Assessment Question score ('Has this medication improved your erections?') went from 0% to 100% in all 28 patients. MUSE-sildenafil combinations were well tolerated in this cohort of patients with excellent patient and partner satisfaction.
Discussion
In this study, highly motivated men who did not have satisfactory results with either sildenafil (Viagra) or MUSE (intraurethral PGE 1 ) were able to achieve erections sufficient for sexual intercourse using a combination of the two therapies. This cohort of patients was composed of both men with organic erectile dysfunction (11=28) and preoperatively potent men who had undergone radical prostatectomy (17=28). Initial dosing was carried out in the clinical setting to assess any adverse events. None were observed.
What is the pharmacologic rationale for the failure of one drug that when used in combination with another results in penile erection rigid enough for penetration? This patient cohort was composed of highly motivated individuals who desired noninvasive or minimally invasive therapy. For this group, despite its efficacy, intracavernosal injection was not an option. This group was composed of 62% of nerve-sparing RRP patients and 38% with vasculogenic erectile dysfunction of varying origins. In all patients, a trial of oral 100 mg of sildenafil citrate failed to result in rigid penile erection, although most patients reported some tumescence. In 60% of patients, MUSE, either at the 500-or 1000-mg dose, also failed to result in rigid penile erection. Why should a combination of drugs be efficacious? It is our hypothesis that sildenafil, by inhibiting trabecular smooth muscle PDE-5 and thus increasing intracellular concentrations of cGMP and MUSE (PGE 1 ) and cAMP synthesis via activation of EP2 and=or EP4 receptors on the smooth muscle cells, results in two different pathways that converge on myosin dephosphorylation and smooth muscle relaxation (Figure 1 ). Since both pathways operate in the normal physiology of erection (cGMP via nitric oxide stimulation of guanylate cyclase and cAMP via vasoactive intestinal polypeptide, calcitonin gene-related peptide, and endogenous PGE stimulation of adenylate cyclase), enhancing intracellular cyclic nucleotide concentrations from both pathways would probably be beneficial. Combination pharmacotherapy has been used in the treatment of erectile dysfunction in an experimental fashion for 25 y, using combinations of cAMP synthesis augmentors (PGE), smooth muscle relaxants and PDE inhibitors (papaverine), and ablockers (phentolamine) injected intracavernosally. Although in this case the endogenous nitric oxide pathway might be expected to contribute to cGMP levels, this is the first report in which pharmacotherapeutic augmentation of both cAMP and cGMP pathways has been attempted in a minimally invasive or noninvasive therapy. 15 What is the evidence for cAMP=cGMP crosstalk or synergy? Processes that increase cAMP may enhance cGMP levels as well. Kim et al 16 have observed that cAMP can inhibit PDE-5 in vitro and treatments that increase cAMP (PGE 1 , forskolin) enhance cGMP synthesis in human corpus cavernosum smooth muscle cells. Repeated intracavernous PGE 1 injections have been reported to up-regulate nitric oxide synthase expression in a rat animal model. 17 Increased cAMP may also dampen the aadrenergic response in corpora cavernosa by downregulating expression of contractile a-adrenergic receptors in the penis. 18 Finally, because this was a group of anxious patients, combination therapy may be much more efficacious in counteracting the potential increased adrenergic tone as a result of circulating catecholamines.
Combination therapy of MUSE and sildenafil is more effective in the salvage of patients who desire noninvasive therapy but in whom single-treatment modalities fail. Although both cAMP-and cGMP-mediated vasodilation can lead to corpus cavernosum smooth muscle relaxation and erection, combining the different mechanistic pathways may succeed where use of a single agent (cAMP or cGMP) fails. This may be in part due to high doses of PGE 1 -inducing contraction in the corpus cavernosum via thromboxane receptors 18 or inability of a single agent to overcome the norepinephrine-induced a-adrenergic mechanism in the penis in anxious patients. Furthermore, although neither MUSE nor sildenafil alone was sufficient to induce erection, blockade of both the cAMP and cGMP pathways may be a means of enhancing trabecular smooth muscle relaxation not unlike what has been reported for intracavernosal injection of single agents (for example, PGE 1 , papaverine) vs doubleagent and triple-agent modalities. In conclusion, in this cohort of 28 patients, MUSE-sildenafil combinations were well tolerated with excellent patient and partner satisfaction. Figure 1 Working hypotheses. Nitric oxide (NO) is generated from neural and endothelial sources and diffuses into corpus cavernosum smooth muscle and binds to soluble guanylate cyclase (GC). Guanosine triphosphate (GTP) is converted to cyclic guanosine monophosphate (cGMP), which ultimately results in smooth muscle relaxation. Phosphodiesterase 5 (PDE-5) converts cGMP to GMP, terminating signal transduction. Prostaglandin E 1 (PGE 1 ) binds to EP2=EP4 receptors, stimulating adenylate cyclase (AC) and converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). cAMP can also lead to smooth muscle relaxation and inhibit PDE-5.
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